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Background
The PI3K-AKT pathway has been shown to complement
activation of the MAPK pathway in melanocyte transfor-
mation in preclinical models. We have utilized clinical
specimens and cell lines to examine the regulation, func-
tional role, and clinical significance of the PI3K-AKT
pathway in melanoma.
Materials and methods
All analyses of clinical specimens were performed under
protocols approved by the MD Anderson Institutional
Review Board. Identities of cell lines were confirmed by
STR-fingerprinting, and cell lines were genotyped by
sequenom analysis for hotspot mutations. Reverse phase
protein array (RPPA) analysis was performed by the MD
Anderson RPPA Core Facility.
Results
Proteomic analysis of frozen melanoma clinical specimens
and cell lines demonstrated that phosphorylation (activa-
tion) of AKT (P-AKT) correlated inversely with PTEN
protein expression. Confirmatory analysis of PTEN expres-
sion by an immunohistochemical (IHC) assay on archival
tumor samples identified a linear correlation between
PTEN measurement by IHC and RPPA. Significantly
increased expression of P-AKT was observed in melano-
mas with complete loss of PTEN protein expression com-
pared to tumors with any other pattern of PTEN
expression. Integrated analysis of BRAF/NRAS mutation
status, PTEN expression, and clinical outcomes was per-
formed using lymphadenectomy specimens from patients
who underwent surgery for stage IIIB/C melanoma. Com-
plete loss of PTEN expression correlated with shorter
overall survival and time to brain metastasis on univariate
and multivariate analyses. Testing of human melanoma
cell lines demonstrated that cells with baseline or compen-
satory activation of the PI3K-AKT pathway were generally
resistant to apoptosis induction following BRAF or MEK
inhibition. Extended molecular profiling found that a sub-
set of melanoma cell lines with de novo and acquired
resistance to MEK inhibitors are characterized by
increased expression of PGC1alpha and a metabolic phe-
notype of high oxidative phosphorylation (OxPhos). The
resistant high OxPhos cell lines all demonstrated synergis-
tic growth inhibition and apoptosis induction with com-
bined targeting of MEK and mTORC1/2. mTORC1/2
inhibition decreased PGC1alpha expression in vitro and in
vivo, and caused cytosolic localization of MITF. Treatment
with a MEK inhibitor and an mTORC1/2 inhibitor
demonstrated marked synergy in a BRAF-mutant, MEK
inhibitor resistant human melanoma cell line in vivo.
Conclusions
Activation of the PI3K-AKT pathway correlates with clini-
cal outcomes and resistance to MAPK pathway inhibitors
in melanoma. These findings support the rationale to
determine the clinical benefit of inhibiting the PI3K-AKT
pathway in this disease.
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